MiRXES, a Singapore biotechnology startup, has appointed Dr David Capes as its senior vice president and new global head of innovation on Sept 20.
In his role, Capes will develop and implement a global innovation strategy that’ll bring MiRXES from a regional small- and medium-sized enterprise (SME) to a global innovation enterprise.
He will also overlook the prioritisation of MiRXES’ clinical pipeline and refine the company’s global regulatory and market entry strategy.
Capes is based in Singapore and will report to MiRXES’ co-founder and CEO, Dr Zhou Lihan.
See also: Singapore biotech startup MiRXES startup raises $104.1 mil in funding
He comes with over 31 years of experience in the biomedical technology industry, which includes general management and strategy, research and development, as well as inorganic opportunity identification and development.
Capes was most recently the vice president of R&D for Greater Asia at Becton-Dickinson (BD). There, he led the team to achieve the revenue target of innovation to new product development (NPD) project approvals by five-fold.
“Innovation has been one of the key driving forces of MiRXES. We are delighted to have David’s expertise in this domain to create a system for innovation where new ideas can be realised and commercialised,” says Zhou.
“I am confident that with David’s distinguished experience in inspiring and mentoring diverse talent, he can strengthen MiRXES’ culture of innovation where our leaders and people can expand their skills on technology innovation, partner engagement and people management, as we continue our global expansion in disease early detection and precision medicine,” he adds.
Photo of MiRXES' founders: The Edge Singapore
